Fingolimod Devatis: Uses, Dosage & Side Effects
An oral sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis in adults with highly active disease
Fingolimod Devatis (fingolimod) is a prescription oral disease-modifying therapy for relapsing-remitting multiple sclerosis (RRMS). It belongs to the sphingosine 1-phosphate (S1P) receptor modulator drug class and works by trapping lymphocytes in lymph nodes, thereby preventing them from crossing the blood-brain barrier and attacking myelin in the central nervous system. Taken as a 0.25 mg hard capsule once daily, fingolimod has been shown in landmark clinical trials (FREEDOMS, TRANSFORMS) to significantly reduce annualized relapse rates by over 50% compared to placebo and to slow disability progression. It is indicated for patients with highly active disease despite prior treatment with a disease-modifying therapy, or in treatment-naive patients with rapidly evolving severe RRMS.
Quick Facts: Fingolimod Devatis
Key Takeaways
- Fingolimod Devatis is an oral once-daily capsule for relapsing-remitting multiple sclerosis, offering a convenient alternative to injectable disease-modifying therapies.
- First-dose cardiac monitoring (minimum 6 hours) is mandatory because fingolimod can cause transient bradycardia and atrioventricular conduction delays.
- Clinical trials demonstrated over 50% reduction in annualized relapse rates compared to placebo, with significant slowing of disability progression.
- Regular monitoring is essential, including eye examinations for macular edema, liver function tests, complete blood counts, and dermatological checks for skin cancers.
- Fingolimod is contraindicated in pregnancy due to risk of fetal harm; women of childbearing potential must use effective contraception during treatment and for 2 months after discontinuation.
What Is Fingolimod Devatis and What Is It Used For?
Fingolimod Devatis contains the active substance fingolimod, a sphingosine 1-phosphate (S1P) receptor modulator that represents an important advancement in the treatment of multiple sclerosis. It was the first oral disease-modifying therapy approved for MS, providing patients with a convenient alternative to injectable treatments such as interferon beta or glatiramer acetate. Fingolimod Devatis is a generic version of the original fingolimod product, offering the same therapeutic benefits at a potentially more accessible cost.
Multiple sclerosis is a chronic autoimmune condition in which the immune system mistakenly attacks the protective myelin sheath surrounding nerve fibers in the brain and spinal cord. This demyelination leads to neurological symptoms including visual disturbances, muscle weakness, numbness, fatigue, and cognitive difficulties. In relapsing-remitting MS, the most common form of the disease, patients experience episodes of new or worsening symptoms (relapses) followed by periods of partial or complete recovery (remissions).
Fingolimod works through a novel mechanism of action. After oral administration and phosphorylation to its active form (fingolimod-phosphate), it binds to S1P receptors (specifically S1P1, S1P3, S1P4, and S1P5) on lymphocytes. This binding causes the internalization and functional degradation of S1P1 receptors, which are essential for lymphocytes to exit lymph nodes. As a result, circulating lymphocytes, particularly the autoreactive T-cells responsible for attacking myelin, are retained in peripheral lymphoid organs and prevented from migrating to the central nervous system. This selective mechanism reduces the inflammatory damage that drives MS progression.
Beyond its immunomodulatory effects, fingolimod may also have direct neuroprotective properties. S1P receptors are expressed on neural cells including oligodendrocytes, astrocytes, and neurons. Preclinical studies suggest that fingolimod may promote remyelination, reduce astrogliosis, and protect neurons from damage, although the clinical significance of these direct CNS effects continues to be investigated.
Fingolimod Devatis is specifically indicated for adult patients with highly active relapsing-remitting MS. This includes patients who have continued to experience relapses despite adequate treatment with at least one disease-modifying therapy, as well as treatment-naive patients with rapidly evolving severe RRMS, defined as two or more disabling relapses in one year with one or more gadolinium-enhancing lesions on brain MRI or a significant increase in T2 lesion load compared to a recent prior MRI.
What Should You Know Before Taking Fingolimod Devatis?
Fingolimod Devatis requires careful pre-treatment evaluation and carries several important contraindications and warnings that both patients and healthcare providers must be aware of. Because fingolimod affects the immune system and has cardiovascular effects, a thorough baseline assessment is essential before initiation.
Contraindications
You should not take Fingolimod Devatis if you have any of the following conditions:
- Known immunodeficiency syndrome: Fingolimod further suppresses immune function and could dangerously compromise patients with pre-existing immunodeficiency.
- Increased risk of opportunistic infections: Including patients receiving immunosuppressive therapies or those who are severely immunocompromised.
- Severe active infections or active chronic infections: Such as hepatitis B or C, tuberculosis, or other active infections that could worsen with immunomodulation.
- Known active malignancies: Except for basal cell carcinoma of the skin, as fingolimod may impair immune surveillance against tumors.
- Severe liver impairment (Child-Pugh class C).
- Certain cardiac conditions: Including myocardial infarction, unstable angina, stroke, or transient ischemic attack within the past 6 months; New York Heart Association (NYHA) Class III/IV heart failure; severe cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III agents; second-degree Mobitz type II or higher AV block, or sick sinus syndrome (unless the patient has a functioning pacemaker); baseline QTc interval of 500 ms or greater.
- Pregnancy and women of childbearing potential not using effective contraception: Fingolimod is teratogenic and must not be used during pregnancy.
- Hypersensitivity to fingolimod or any of the excipients.
Warnings and Precautions
The first dose of fingolimod causes a transient decrease in heart rate. All patients must be monitored for at least 6 hours after the first dose with continuous ECG monitoring, hourly blood pressure and pulse measurements. Extended monitoring may be required for patients with pre-existing cardiac conditions or those taking heart rate-lowering medications.
Bradycardia and AV conduction delays: Fingolimod causes a dose-dependent transient reduction in heart rate, with the maximum decrease typically occurring within 6 hours of the first dose. Heart rate usually returns toward baseline within the first month of treatment. In clinical trials, first-degree AV block was observed in approximately 4.7% of patients receiving fingolimod 0.5 mg, compared to 1.5% on placebo. Second-degree AV block (Mobitz type I) occurred rarely. Patients should be informed of symptoms to watch for, including dizziness, lightheadedness, palpitations, and chest pain.
Infections: Fingolimod reduces the peripheral lymphocyte count to approximately 20-30% of baseline values. This increases susceptibility to infections. Before starting treatment, a recent complete blood count (within 6 months) should be available. Fingolimod should not be initiated in patients with a severe active infection until the infection has resolved. Patients should be monitored for signs and symptoms of infection during treatment and for 2 months after discontinuation, as lymphocyte counts may take 1-2 months to return to normal.
Before initiating fingolimod, patients without a documented history of chickenpox or prior vaccination should be tested for antibodies to varicella zoster virus. If antibodies are absent, vaccination is recommended at least 1 month before starting fingolimod. Rare but serious cases of varicella zoster disseminated infection and encephalitis have been reported.
Macular edema: Fingolimod can cause macular edema, typically within the first 3-4 months of treatment. An ophthalmologic evaluation is required at baseline and at 3-4 months after starting treatment. Patients with a history of uveitis or diabetes mellitus are at increased risk and should have more frequent eye examinations. Macular edema usually resolves after discontinuation of fingolimod, though some patients may have residual visual effects.
Liver function: Elevations in liver transaminases, particularly alanine aminotransferase (ALT), have been reported with fingolimod. Recent liver function tests (within 6 months) should be available before starting treatment. Liver function should be monitored periodically during treatment, and fingolimod should be discontinued if ALT rises to more than 5 times the upper limit of normal.
Progressive multifocal leukoencephalopathy (PML): Rare cases of PML, a serious and potentially fatal brain infection caused by the JC virus, have been reported in patients treated with fingolimod. PML typically occurs in immunocompromised patients. Healthcare providers should be vigilant for symptoms suggestive of PML, such as progressive cognitive deterioration, visual field defects, or new neurological symptoms not attributable to MS. If PML is suspected, fingolimod should be stopped immediately and appropriate diagnostic evaluation performed.
Posterior reversible encephalopathy syndrome (PRES): Rare cases of PRES have been reported with fingolimod. Symptoms may include sudden onset of severe headache, altered mental status, visual disturbances, and seizures. If PRES is suspected, fingolimod should be discontinued.
Skin malignancies: Cases of basal cell carcinoma and melanoma have been reported with fingolimod. A dermatological examination is recommended before starting treatment and periodically thereafter. Patients should be advised to protect themselves from sun exposure and UV light, and suspicious skin lesions should be promptly evaluated.
Pregnancy and Breastfeeding
Fingolimod is contraindicated in pregnancy. Animal studies have demonstrated reproductive toxicity including teratogenicity (congenital malformations, particularly ventricular septal defect and other cardiovascular abnormalities) and embryo-fetal death. Post-marketing data have confirmed an approximately two-fold increased risk of major congenital malformations in infants exposed to fingolimod during the first trimester.
Women of childbearing potential must:
- Have a negative pregnancy test before starting treatment
- Be counseled on the serious risk of fetal harm
- Use effective contraception during treatment and for 2 months after discontinuation
- Immediately inform their doctor if they become pregnant or suspect pregnancy
If a woman becomes pregnant while taking fingolimod, the medication must be stopped immediately and the patient referred for specialist obstetric monitoring. The 2-month washout period is necessary because of fingolimod's long elimination half-life (6-9 days).
Breastfeeding: Fingolimod is excreted in breast milk in animal studies. Because of the potential for serious adverse reactions in breastfed infants, including immunosuppression, breastfeeding is not recommended during treatment with fingolimod or for 2 months after discontinuation.
Fertility: No dedicated human fertility studies have been performed. Animal data did not indicate adverse effects on fertility at clinically relevant doses, although fingolimod may have effects on uterine smooth muscle and could theoretically impact implantation.
How Does Fingolimod Devatis Interact with Other Drugs?
Understanding drug interactions with fingolimod is critical for safe and effective use. Because fingolimod affects heart rate, immune function, and is metabolized by specific enzymes, several categories of medications require special consideration. Always inform your neurologist or prescribing physician of all medications you are taking, including prescription drugs, over-the-counter medications, and herbal supplements.
Major Interactions
Heart rate-lowering medications: Fingolimod should not be co-administered with beta-blockers (e.g., atenolol, metoprolol, propranolol) or heart rate-lowering calcium channel blockers (e.g., verapamil, diltiazem) without careful cardiac risk assessment. The combination may result in additive effects on heart rate reduction, increasing the risk of severe bradycardia or heart block. If co-administration is unavoidable, extended first-dose monitoring (at least 24 hours) is recommended, and cardiology consultation should be sought.
Antiarrhythmic drugs: Fingolimod must not be used concurrently with Class Ia antiarrhythmics (quinidine, procainamide, disopyramide) or Class III antiarrhythmics (amiodarone, dronedarone, sotalol, dofetilide). These agents can cause bradycardia and QT prolongation, and the combination with fingolimod could lead to potentially life-threatening cardiac arrhythmias, including torsades de pointes.
Immunosuppressive or immunomodulatory therapies: Concurrent use with other immunosuppressive medications (e.g., azathioprine, cyclosporine, mycophenolate, methotrexate) or certain disease-modifying MS therapies (e.g., natalizumab, alemtuzumab, ocrelizumab) increases the risk of additive immunosuppression and serious infections. When switching from or to fingolimod, adequate washout periods must be observed to minimize the risk of overlapping immunosuppressive effects.
Live attenuated vaccines: Vaccination with live attenuated vaccines (e.g., measles, mumps, rubella, varicella, yellow fever, BCG) should be avoided during fingolimod treatment and for 2 months after discontinuation. The immunosuppressive effect of fingolimod may reduce the immune response to vaccines and increase the risk of infection from live vaccines. Inactivated vaccines may be administered, though their efficacy may be reduced.
Minor Interactions
QT-prolonging medications: Caution is advised when fingolimod is used with other medications that can prolong the QT interval, such as certain antidepressants (citalopram, escitalopram), antipsychotics (haloperidol, quetiapine), antibiotics (azithromycin, moxifloxacin, erythromycin), and antimalarials (chloroquine, hydroxychloroquine). ECG monitoring may be warranted.
CYP enzyme interactions: Fingolimod is primarily metabolized by CYP4F2 and to a lesser extent by CYP2D6, CYP2E1, CYP3A4, and CYP4F12. Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) may increase fingolimod exposure, though clinically significant interactions appear modest. Fingolimod is not a significant inhibitor or inducer of CYP enzymes and is unlikely to affect the metabolism of other drugs.
Corticosteroids: Short courses of corticosteroids for MS relapse management can be used alongside fingolimod. However, prolonged concomitant use of systemic corticosteroids increases the risk of additive immunosuppression.
| Interacting Drug / Class | Interaction Effect | Severity | Recommendation |
|---|---|---|---|
| Beta-blockers (atenolol, metoprolol) | Additive bradycardia, increased risk of AV block | Major | Avoid or extend first-dose monitoring to 24 hours |
| Class Ia/III antiarrhythmics (amiodarone, sotalol) | Risk of torsades de pointes, severe bradycardia | Contraindicated | Do not co-administer |
| Verapamil, diltiazem | Additive heart rate reduction | Major | Avoid or extended cardiac monitoring |
| Immunosuppressants (azathioprine, cyclosporine) | Additive immunosuppression, increased infection risk | Major | Avoid concomitant use; observe washout periods |
| Live attenuated vaccines | Reduced vaccine efficacy, risk of infection | Major | Avoid during treatment and 2 months after stopping |
| Ketoconazole (CYP3A4 inhibitor) | Increased fingolimod exposure (~1.7-fold AUC) | Moderate | Use with caution; monitor for adverse effects |
| QT-prolonging medications | Additive QT prolongation | Moderate | ECG monitoring recommended |
| Corticosteroids (short course) | Minimal additive immunosuppression | Low | Short courses for relapses are acceptable |
What Is the Correct Dosage of Fingolimod Devatis?
Fingolimod Devatis should only be prescribed and supervised by a physician experienced in the management of multiple sclerosis. The dosing regimen is straightforward, but initiation and monitoring require careful clinical attention.
Adults
Standard Adult Dose
The recommended dose is 0.25 mg (one capsule) taken orally once daily. The capsule can be taken with or without food. It should be swallowed whole and not opened, crushed, or chewed. The capsule should be taken at approximately the same time each day to maintain consistent blood levels.
Treatment initiation requires first-dose cardiac monitoring. All patients must remain at the clinic or hospital for at least 6 hours after taking the first dose. During this period, continuous ECG monitoring, hourly blood pressure and heart rate measurements should be performed. If the heart rate at the end of the 6-hour observation period is at its lowest point, monitoring must be extended for at least 2 additional hours and until the heart rate increases. If symptomatic bradycardia, bradyarrhythmia, or a new onset of second-degree or higher AV block occurs during the monitoring period, appropriate clinical management should be instituted and monitoring continued overnight.
First-dose monitoring procedures should also be applied when treatment is re-initiated after an interruption of more than 14 consecutive days during the first 2 weeks of treatment, after an interruption of more than 7 consecutive days during weeks 3 and 4 of treatment, or after an interruption of more than 14 consecutive days after one month of treatment.
Children
Pediatric Use
Fingolimod Devatis 0.25 mg capsules are not approved for use in children and adolescents under 18 years of age. The safety and efficacy of this specific product have not been established in pediatric populations. Note that some fingolimod products are available in lower doses for pediatric patients; consult current guidelines and approved labeling for the specific product being considered.
Elderly
Use in Elderly Patients (65 years and older)
Limited clinical experience exists with fingolimod in patients aged 65 years and older. No dose adjustment is recommended, but elderly patients should be treated with caution due to the potentially higher incidence of cardiovascular disease, decreased hepatic and renal function, and concomitant medication use in this population. The risk of infections and macular edema may also be increased in older patients.
No dose adjustment is required for patients with mild to moderate renal impairment. Fingolimod has not been studied in patients with severe renal impairment or on dialysis. For hepatic impairment, no dose adjustment is needed for mild to moderate impairment (Child-Pugh class A or B), but close monitoring is recommended. Fingolimod is contraindicated in severe hepatic impairment (Child-Pugh class C).
Missed Dose
If a dose is missed, skip the missed dose and take the next dose at the regularly scheduled time. Do not take a double dose to make up for a missed dose. If treatment is interrupted for the duration specified above (depending on the phase of treatment), contact your neurologist before resuming, as first-dose monitoring may need to be repeated.
Overdose
In case of overdose, seek immediate medical attention. Fingolimod overdose could potentially lead to severe and prolonged bradycardia. Continuous cardiac monitoring should be instituted. Standard supportive care should be provided. Fingolimod cannot be removed by dialysis or plasma exchange. In clinical trials, single doses of up to 40 mg (160 times the therapeutic dose) were generally well tolerated, though one subject experienced transient mild chest tightness and palpitations at the 40 mg dose. In cases of overdose, an isoproterenol infusion may be considered for refractory symptomatic bradycardia, but atropine is typically ineffective in reversing fingolimod-induced bradycardia because the mechanism is not vagally mediated.
| Patient Group | Dose | Frequency | Special Considerations |
|---|---|---|---|
| Adults (18+ years) | 0.25 mg | Once daily | First-dose cardiac monitoring required (minimum 6 hours) |
| Children (<18 years) | N/A | N/A | Not approved for pediatric use with this product |
| Elderly (65+ years) | 0.25 mg | Once daily | Use with caution; increased monitoring recommended |
| Hepatic impairment (mild-moderate) | 0.25 mg | Once daily | No dose adjustment; monitor liver function closely |
| Severe hepatic impairment | N/A | N/A | Contraindicated (Child-Pugh class C) |
What Are the Side Effects of Fingolimod Devatis?
Like all medicines, Fingolimod Devatis can cause side effects, although not everybody gets them. The side effects listed below are based on data from clinical trials and post-marketing surveillance. Most side effects are mild to moderate in severity and manageable with appropriate monitoring and clinical care. It is important to understand the frequency categories used in medicine to properly assess your individual risk.
The safety profile of fingolimod has been extensively characterized through pivotal clinical trials (FREEDOMS, FREEDOMS II, TRANSFORMS) involving more than 3,500 patients, as well as extensive post-marketing experience spanning over a decade of clinical use worldwide. The following side effects have been reported:
Very Common
Affects more than 1 in 10 patients
- Influenza viral infections
- Headache
- Cough
- Diarrhea
- Elevated liver transaminases (ALT/AST)
- Back pain
- Lymphopenia (reduced lymphocyte count)
Common
Affects 1 to 10 in 100 patients
- Herpes viral infections (oral herpes, herpes zoster)
- Bronchitis
- Sinusitis
- Gastroenteritis
- Tinea infections (fungal skin infections)
- Depression
- Dizziness
- Migraine
- Blurred vision
- Macular edema
- Bradycardia (slow heart rate)
- Atrioventricular block (first- or second-degree)
- Hypertension (high blood pressure)
- Dyspnea (shortness of breath)
- Eczema, alopecia (hair loss), pruritus (itching)
- Muscle spasms
- Asthenia (weakness), fatigue
- Elevated gamma-glutamyl transferase (GGT)
- Decreased weight
- Leukopenia (reduced white blood cell count)
Uncommon
Affects 1 to 10 in 1,000 patients
- Pneumonia
- Nausea
- Thrombocytopenia (low platelet count)
- Neutropenia (low neutrophil count)
- Depressed mood
- Posterior reversible encephalopathy syndrome (PRES)
Rare
Affects 1 to 10 in 10,000 patients
- Progressive multifocal leukoencephalopathy (PML)
- Cryptococcal infections (meningitis, disseminated)
- Lymphoma
- Squamous cell carcinoma
- Basal cell carcinoma
- Kaposi sarcoma
- Hemophagocytic syndrome
- Peripheral arterial occlusive disease
Not Known
Frequency cannot be estimated from available data
- Reactivation of hepatitis B virus
- Immune reconstitution inflammatory syndrome (IRIS) after discontinuation
- Severe worsening of MS disease after fingolimod discontinuation (rebound)
- Tumefactive MS lesions
Contact your doctor or seek emergency medical care immediately if you experience: sudden severe headache, confusion, seizures, or vision changes (possible PML or PRES); signs of serious infection such as high fever, severe cough, or unusual skin infections; new or worsening visual problems (possible macular edema); chest pain, prolonged dizziness, fainting, or irregular heartbeat; yellowing of skin or eyes, dark urine, or unusual abdominal pain (possible liver problems); or any new skin growths or changes in existing moles.
Rebound effect after discontinuation: A small number of patients have experienced severe disease rebound after stopping fingolimod, with significant increase in relapse frequency and new MRI lesion activity, sometimes exceeding pre-treatment levels. This is thought to occur as lymphocytes rapidly re-enter the circulation and CNS after removal of the S1P receptor blockade. To minimize this risk, neurologists typically plan a transition to an alternative disease-modifying therapy before or shortly after discontinuation of fingolimod, and patients should be closely monitored for rebound disease activity for several months.
How Should You Store Fingolimod Devatis?
Proper storage of Fingolimod Devatis is important to ensure the medication remains effective and safe throughout its shelf life. Follow these storage guidelines carefully:
- Temperature: Store below 25°C (77°F). Do not refrigerate or freeze.
- Moisture protection: Store in the original blister packaging to protect from moisture. Do not remove capsules from the blister until you are ready to take the dose.
- Light protection: No special light protection requirements, but keeping the capsules in the original packaging is recommended.
- Keep out of reach and sight of children: Store the medication in a secure location where children cannot access it.
- Expiry date: Do not use Fingolimod Devatis after the expiry date stated on the carton and blister after "EXP." The expiry date refers to the last day of that month.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment. If you notice any visible signs of deterioration, such as discoloration, unusual odor, or damaged capsules, do not take the medication and consult your pharmacist.
What Does Fingolimod Devatis Contain?
Understanding the full composition of your medication is important, particularly if you have known allergies to any ingredients. Fingolimod Devatis 0.25 mg hard capsules contain the following:
Active substance: Each capsule contains 0.25 mg fingolimod (as fingolimod hydrochloride, equivalent to 0.28 mg fingolimod hydrochloride).
Excipients (inactive ingredients):
- Capsule contents: Mannitol, magnesium stearate, and hydroxypropyl cellulose (low substituted). Mannitol serves as a filler and diluent, magnesium stearate is a lubricant used in capsule manufacturing, and hydroxypropyl cellulose acts as a binder and disintegrant.
- Capsule shell: Gelatin, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172), and black iron oxide (E172). These colorants give the capsule its characteristic appearance and help distinguish it from other medications.
- Printing ink: Shellac, black iron oxide (E172), propylene glycol, and ammonia solution (concentrated). The printing ink is used to print identifying information on the capsule shell.
Appearance: Fingolimod Devatis 0.25 mg is a hard capsule with a characteristic appearance as described in the product packaging. Each capsule is imprinted with identifying text for clear identification. The capsules are packed in PVC/PVDC/aluminium blisters.
If you have a known allergy or intolerance to any of the listed excipients, particularly gelatin (which is of animal origin) or any of the colorants (iron oxides), inform your doctor or pharmacist before starting treatment. Alternative formulations or products may be available.
Frequently Asked Questions About Fingolimod Devatis
Fingolimod Devatis is a generic version of Gilenya, both containing the same active substance, fingolimod, at the same 0.25 mg dose. Generic medicines must meet the same rigorous quality, safety, and efficacy standards as the original (reference) product. The European Medicines Agency (EMA) requires generic medicines to demonstrate bioequivalence, meaning they deliver the same amount of active ingredient to the body at the same rate. The primary differences are the manufacturer, the inactive excipients (which vary slightly between products), and typically the cost, as generics are usually less expensive. The clinical effect, side effect profile, and dosing regimen are the same.
Fingolimod is a long-term treatment for multiple sclerosis. The duration of treatment is determined by your neurologist based on your individual disease course, treatment response, and tolerability. Many patients remain on fingolimod for several years. Clinical trial data extends to 10+ years of follow-up, demonstrating sustained efficacy and an acceptable long-term safety profile. You should not stop taking fingolimod without consulting your neurologist, as abrupt discontinuation can lead to disease rebound. If a switch to another therapy is planned, your neurologist will manage the transition to minimize the risk of rebound disease activity.
There is no specific interaction between fingolimod and alcohol. However, both fingolimod and alcohol can affect liver function, and fingolimod is known to cause elevated liver enzymes. Excessive alcohol consumption could compound the hepatotoxic risk. Moderate alcohol consumption is generally considered acceptable, but you should discuss this with your neurologist, particularly if you have pre-existing liver conditions or elevated liver enzymes. Your liver function should be monitored regularly throughout treatment regardless of alcohol intake.
If you miss a single dose, skip the missed dose and take the next dose at your usual time the following day. Do not take a double dose. If you miss more than a specified number of consecutive days (depending on how long you have been on treatment), you may need to repeat the first-dose monitoring procedure. Specifically, if you miss more than 14 consecutive days during the first two weeks of treatment, more than 7 consecutive days during weeks 3-4, or more than 14 consecutive days after one month of treatment, contact your neurologist before resuming, as first-dose cardiac monitoring will likely need to be repeated.
Yes. Fingolimod works by reducing the number of lymphocytes (a type of white blood cell) circulating in your blood to approximately 20-30% of normal levels. This is part of how the drug works to treat MS, but it also means your immune system is somewhat suppressed and you may be more susceptible to infections. Common infections include upper respiratory tract infections, urinary tract infections, and herpes virus reactivation. Rare but serious infections like progressive multifocal leukoencephalopathy (PML) and cryptococcal meningitis have been reported. You should report any signs of infection to your doctor promptly, practice good hygiene, stay up to date with recommended inactivated vaccinations, and avoid live vaccines.
Yes, but the transition must be carefully managed by your neurologist. When switching from interferon beta or glatiramer acetate, fingolimod can generally be started immediately, provided there are no signs of significant treatment-related immunosuppression. When switching from natalizumab, a washout period of approximately 4-8 weeks is usually recommended to allow immune function to recover before starting fingolimod, while balancing the risk of disease reactivation. When switching from other immunosuppressants (e.g., mitoxantrone, azathioprine), longer washout periods may be necessary. A baseline blood count confirming adequate lymphocyte levels should be obtained before starting fingolimod.
References
- European Medicines Agency (EMA). Fingolimod - Summary of Product Characteristics. EMA/CHMP. Last updated 2025.
- U.S. Food and Drug Administration (FDA). Gilenya (fingolimod) - Highlights of Prescribing Information. FDA Label. Last revised 2024.
- Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401. doi:10.1056/NEJMoa0909494 (FREEDOMS trial).
- Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-415. doi:10.1056/NEJMoa0907839 (TRANSFORMS trial).
- Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545-556.
- Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with relapsing multiple sclerosis. Mult Scler. 2024;30(2):157-174.
- Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018;90(17):777-788. doi:10.1212/WNL.0000000000005347 (AAN guidelines, updated 2024).
- Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9(11):883-897.
- Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011;69(5):759-777.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd edition. WHO; 2023.
Editorial Team
Medical Content
iMedic Medical Editorial Team - Specialists in Neurology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board - Independent panel following EMA, FDA, and ECTRIMS/EAN guidelines
Evidence Standard
Level 1A - Systematic reviews and meta-analyses of randomized controlled trials (GRADE framework)
Conflict of Interest
No pharmaceutical industry funding. Independent medical editorial content with no commercial sponsorship.
Last reviewed: | Next review due: | Our editorial process